Episode 23: A Between the Biotech Waves conversation with Jim Birchenough, Vice Chair of Wells Fargo Biopharmaceutical Inv Banking

1

Introduction

00:00 • 3min

2

Is the Cycle of Biotechnics Going on So Long?

02:44 • 4min

3

Are You Seeing a Cash Runway?

06:33 • 2min

4

Is Volume Driven Investing a Good Thing?

08:42 • 2min

5

Are the M&A Financings of the Past a Good Idea?

10:41 • 2min

6

Is the Consolidation Making Healthier Companies?

12:39 • 2min

7

Are We Seeing More Realistic Approaches to Prosecution of Clinical Trials?

14:47 • 4min

8

Do You Think We're Going to See a Recovery in Q1?

18:54 • 3min

9

Is There a Pain Point Now?

21:27 • 4min

10

Gene Therapy

25:36 • 2min

11

Is the Inflation Reduction Act Positive Negative in Your Mind?

27:33 • 2min

12

Is Now the Time to IPO?

29:08 • 4min

13

Do You Think We've Got a Full Reset of Public Market Valuation?

32:59 • 3min

14

Is There a Step Up in the IPO?

36:14 • 2min

15

Is Insider Participation a Relatively High Thing?

38:28 • 2min

16

Is the T.T.W. Process Helping Investors?

40:14 • 3min

17

Is There Enough Capital on the Sidelines to Really Support the Sector?

43:44 • 2min

18

Is FDA a Gatekeeper to Biotech?

45:44 • 3min

19

Do You Think We're Facing Challenges With New Modalities?

48:32 • 3min

20

Patient Advocacy - Is There a Danger of FDA Become More Hawkish?

51:57 • 2min

21

Is 2023 Going to Be a Good Year?

53:57 • 3min